GlassScriptPhysician profile
Joshua Slusher
NPI 1649709478
$1,141.75
in general payments reported to CMS, 2019-2025
18 companies · $764 in 2025
The $764 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $59.05 · 2024: $319 · 2025: $764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,141.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $275.56 | 2024-2025 | |
| Pfizer INC. | $177.66 | 2024-2025 | |
| Abiomed | $111.41 | 2024 | Impella |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.04 | 2023-2025 | Xifaxan |
| Lilly USA, LLC | $79.83 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Phathom Pharmaceuticals, INC. | $60.79 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $54.03 | 2025 | |
| Astellas Pharma US INC | $52.51 | 2025 | Veozah |
| Amgen INC. | $40.12 | 2023-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $31.14 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $25.06 | 2025 | Freestyle Libre 3 |
| Hologic Sales and Service, LLC | $22.92 | 2025 | Aptima, Thinprep 2000 Processor |
| Glaxosmithkline, LLC. | $22.73 | 2024 | Shingrix, Arexvy, Bexsero |
| Sumitomo Pharma America, INC. | $21.10 | 2024 | Gemtesa |
| Medtronic, INC. | $18.71 | 2025 | Minimed 780g |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $17.40 | 2025 | Cequr Simplicity |
| Astrazeneca Pharmaceuticals LP | $15.51 | 2024 | Breztri |
| Lundbeck LLC | $15.23 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Slusher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.